Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Bookmark and Share
Published: 14 Sep 2021
Views: 143
Rating:
Save
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Dr Enrique Ocio talks to ecancer about the update of safety and efficacy of isatuximab short-duration fixed-volume infusion plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.

He begins by talking about the methodology explaining that the study was split into 2 parts. Part A, a weight-based infusion of IsaVRd was effective and well tolerated (median infusion duration at first infusion, 3.7 hours). Part B, where Isa (10 mg/kg) was administered as a fixed-volume infusion of 250 mL with standard doses of VRd. The primary endpoint is the complete response rate of Isa-VRd.

Dr Ocio then talks about the findings and how the median duration of Isa infusion decreased to 1.3 hours from the third infusion onward.
The overall response rate was 97.8%, including a CR/stringent CR (sCR) rate of 35.6% and very good partial response rate of 55.6%.

He concludes that results confirm the feasibility, efficacy, and safety of the approved short-duration fixed-volume infusion method of Isa in combination with VRd in patients with NDMM ineligible/with no immediate intent for ASCT.

Isa-VRd is under investigation in ongoing Phase 3 studies.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

 

Related Videos

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve ef...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )
17 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invas...
Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invasive bladder cancer ( Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy )
19 Jul 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...
Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )
11 Jun 2021
IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy...
Prof Heather Wakelee - Stanford University, Stanford, USA
IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC ( Prof Heather Wakelee - Stanford University, Stanford, USA )
11 Jun 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021